Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy

BACKGROUND: Programmed death-ligand 1 (PD-L1) is an important immune checkpoint protein that can be regarded as a pan-cancer antigen expressed by multiple different cell types within the tumor. While antagonizing PD-L1 is well known to relieve PD-1/PD-L1-mediated T cell suppression, here we have com...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalique, Hena, Baugh, Richard, Dyer, Arthur, Scott, Eleanor M., Frost, Sally, Larkin, Sarah, Lei-Rossmann, Janet, Seymour, Leonard W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026026/
https://www.ncbi.nlm.nih.gov/pubmed/33820820
http://dx.doi.org/10.1136/jitc-2020-001292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026026/
https://www.ncbi.nlm.nih.gov/pubmed/33820820
http://dx.doi.org/10.1136/jitc-2020-001292

Ejemplares similares